La vendita allo scoperto per Ginkgo Bioworks Holdings dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Ginkgo Bioworks Holdings. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Ginkgo Bioworks Holdings (NYSE:DNA) Azioni, Report sulle vendite allo scoperto

Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering and BiosecurityThe majority of revenue in the company comes from the Biosecurity segment, which charges fees for data analytics and services.

Ginkgo Bioworks Holdings, Inc. Class A Common Stock

Ginkgo Bioworks Holdings Inc

Metaverse Dualchain Network Architecture

DeNA Co Ltd

DNAPRINT GENOMICS INC by DNAPrint Genomics, Inc.

DNA Print Genomics Inc

DNA Brands Inc

Scotiabank analyst Patrick Colville maintains Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) with a Sector Perform and raises the price target from $85 to $87.

News

Price Target

Analyst Ratings

Scotiabank Maintains Sector Perform on Cloudflare, Raises Price Target to $87

China&#8217;s central government announced a new fiscal stimulus package worth 6 trillion yuan ($840 billion) to ease local governments&#8217; hidden debt burdens. This expansive financial program, set to be implemented by the end of 2026, marks a significant move by Beijing to address mounting economic pressures and revive growth amid global uncertainties.
The new stimulus plan, confirmed by China&#8217;s Minister of Finance Lan Fo&#8217;an, will allocate around 2 trillion yuan annually to local authorities, CNBC <a target="_blank" href="https://www.cnbc.com/2024/11/08/china-expected-to-announce-highly-anticipated-fiscal-stimulus-package.html" rel="noreferrer noopener">reports</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41812585/datadog-beats-q3-estimates-margins-show-mixed-results" rel="noreferrer noopener">Datadog Beats Q3 Estimates, Margins Show Mixed Results</a>
Additionally, central authorities will issue 800 billion yuan annually in special local government bonds, totaling 4 trillion yuan over the next five years. These measures are part of a broader strategy to reduce local hidden debt from 14.3 trillion yuan to 2.3 trillion yuan by 2028.
U.S.-listed Chinese stocks&nbsp;Alibaba Group Holding.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>),&nbsp;JD.com, Inc.&nbsp;(NASDAQ:&nbsp;JD),&nbsp;Baidu, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>),&nbsp;NIO Inc.&nbsp;(NYSE:&nbsp;NIO),&nbsp;Li Auto Inc.&nbsp;(NASDAQ:&nbsp;LI),&nbsp;and XPeng Inc.&nbsp;(NYSE:&nbsp;XPEV)&nbsp;are trading lower Friday as the stimulus failed to impress the Street <a target="_blank" href="https://www.benzinga.com/government/24/11/41806635/whats-going-on-with-us-listed-chinese-stocks-like-alibaba-jd-nio-on-thursday" rel="noreferrer noopener">which expected over</a> 10 trillion yuan ($1.39 billion) in financial support, focused on local government debt and real estate.
The financial package comes as the Chinese economy faces lingering challenges, including a real estate market slump and weaker local government revenues post-pandemic. During a press briefing, Minister Lan emphasized the urgency of addressing hidden local debts, which have ballooned to an estimated 50-60 trillion yuan ($7-8.4 trillion), according to projections by Nomura. This new initiative aims to help local governments manage interest payments, potentially saving up to 300 billion yuan annually.
China&#8217;s parliament, the National People&#8217;s Congress, is expected to formally approve the increased debt issuance quotas during its current legislative session. The move follows recent stimulus discussions led by President Xi Jinping and earlier efforts by the People&#8217;s Bank of China, which included interest rate cuts to support the economy. Market analysts anticipate heightened fiscal support after Donald Trump&#8217;s election, which may reignite trade tensions between the U.S. and China.
China aims to counter potential <a target="_blank" href="https://www.benzinga.com/government/24/11/41806635/whats-going-on-with-us-listed-chinese-stocks-like-alibaba-jd-nio-on-thursday" rel="noreferrer noopener">&#8220;Trump shocks&#8221; on trade</a> with its latest fiscal move.
After Trump&#8217;s victory, Chinese stocks declined while U.S. markets surged. During his campaign, Trump suggested boosting tariffs on Chinese imports by up to 60%. Such hikes might slash Chinese exports to the U.S. by around $200 billion and cut one percentage point from China&#8217;s GDP, according to former economic planning official Zhu Baoliang, cited by CNBC.
Price Actions:&nbsp;At the last check on Friday, BABA stock is down 3.28% at $96.86 premarket. JD is down 3.44%, BIDU is down 2.20%, NIO is down 2.26%, LI is down 4.96%, and XPEV is down 2.74%.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41812311/appian-projects-positive-adjusted-ebitda-boasts-strong-subscription-revenue-in-q3" target="_blank" rel="noreferrer noopener">Appian Projects Positive Adjusted EBITDA, Boasts Strong Subscription Revenue In Q3</a></li>
</ul>
Photo Via Shutterstock

Government

Regulations

Media

BABA

BIDU

China's Stimulus Plan Not Enough To Ignite Stocks

Kentucky Governor <a href="https://www.benzinga.com/topic/andy-beshear">Andy Beshear</a> (D) hailed the outcome of Tuesday's election as a decisive statement on medical cannabis reform. In an election process that had bipartisan and widespread support, voters in over 100 cities and counties across the state approved local measures to permit medical marijuana businesses in their towns and jurisdictions.
Beshear, <a href="https://www.benzinga.com/markets/cannabis/23/03/31612072/kentucky-becomes-38th-state-to-legalize-medical-marijuana-as-gov-beshear-signs-bill-into-law">who signed a medical marijuana legalization bill </a>into law last year, declared that the results confirm what many already believed: Kentuckians support cannabis reform.
"This signals what we have known for a long time, which is that the jury is no longer out on medical cannabis," Beshear <a href="https://www.kentucky.gov/Pages/Activity-stream.aspx?n=GovernorBeshear&amp;prId=2333">said</a> in his weekly new conference Thursday. "Kentuckians want their families, friends and neighbors who have serious medical conditions &#8211; like cancer, multiple sclerosis or PTSD &#8211; to have safe and affordable access. We are keeping our promise to make sure they will."
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41775201/cannabis-reform-stumbles-in-2024-elections-a-state-by-state-breakdown-as-stocks-take-a-hit">Cannabis Reform Stumbles In 2024 Elections: A State-By-State Breakdown As Stocks Take A Hit</a>
All 53 cities and 53 counties presented with medical cannabis measures in Kentucky approved them, with over 340,000 votes cast in favor. This continues a trend in the state where more than 40 cities have already authorized marijuana businesses and only 20 jurisdictions have opted to ban them.
"We saw overwhelming support at the polls for our new system of medical cannabis," Beshear said, noting the uniform wins for the measures. "In every single place that medical cannabis was put on the ballot, it won &#8211; meaning citizens of every part of Kentucky said that it is time and they want to see this option in their community."
Of the state&#8217;s 106 ballot measures, no counties or cities opted to bar medical marijuana businesses from operating in their borders, according to data <a href="https://x.com/Hicks_JustinM/status/1854016544038158830">compiled </a>by Louisville Public Media&#8217;s Justin Hicks at WFPL News who <a href="https://x.com/WFPLNews">noted </a>that "every single county and every single city voted to approve medical cannabis businesses."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">According to my scraping of Kentucky local elections, &#x2A;every single county&#x2A; and &#x2A;every single city&#x2A; voted to approve medical cannabis businesses. <a href="https://t.co/FAVRN0HghV">pic.twitter.com/FAVRN0HghV</a>
&mdash; Justin Hicks (@Hicks_JustinM) <a href="https://twitter.com/Hicks_JustinM/status/1854016544038158830?ref_src=twsrc%5Etfw">November 6, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Kentucky stood apart in this year&#8217;s elections as <a href="https://www.benzinga.com/markets/cannabis/24/11/41775201/cannabis-reform-stumbles-in-2024-elections-a-state-by-state-breakdown-as-stocks-take-a-hit">cannabis reform ballots failed </a>in North Dakota, South Dakota and Florida.
Kentucky&#8217;s new medical marijuana law will come into effect in January 2025. Preparations by the Office of Medical Cannabis (OCM) include <a href="https://www.benzinga.com/markets/cannabis/24/10/41608654/kentucky-and-delaware-held-cannabis-licensing-lotteries-ushering-in-new-regulated-marketshttps://www.benzinga.com/markets/cannabis/24/10/41608654/kentucky-and-delaware-held-cannabis-licensing-lotteries-ushering-in-new-regulated-markets">recent lotteries for approving</a> cultivators, processors and testing facilities, with a dispensary lottery scheduled for Dec. 16. Starting Dec. 1, physicians will be able to issue medical marijuana recommendations, and patients can begin applying for their cannabis cards on Jan. 1.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/41829368/overdose-crisis-in-shadows-of-elections-as-black-indigenous-americans-deaths-rise">Overdose Crisis In Shadows Of Elections As Black, Indigenous Americans Deaths Rise</a></li>
</ul>
Government photo&nbsp;of Andy Beshear

Cannabis

Health Care

Legal

Kentucky Gov. Beshear: 'The Jury Is No Longer Out,' Kentuckians Want Medical Cannabis

Piper Sandler analyst Peter Keith reiterates YETI Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YETI#NYSE">YETI</a>) with a Overweight and lowers the price target from $55 to $54.

Reiteration

YETI

Piper Sandler Reiterates Overweight on YETI Holdings, Lowers Price Target to $54

Scotiabank analyst Konark Gupta maintains Chorus Aviation (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CHR#TSX">CHR</a>) with a Sector Perform and raises the price target from C$3.25 to C$3.4.

TSX:CHR

Scotiabank Maintains Sector Perform on Chorus Aviation, Raises Price Target to C$3.4

WIIM

FTRE

Fortrea shares are trading higher after the company issued FY24 revenue guidance above estimates.

Piper Sandler analyst Thomas Champion reiterates Pinterest (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) with a Overweight and lowers the price target from $45 to $41.

PINS

Piper Sandler Reiterates Overweight on Pinterest, Lowers Price Target to $41

Piper Sandler analyst Alexander Potter maintains Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) with a Overweight and lowers the price target from $21 to $19.

RIVN

Piper Sandler Maintains Overweight on Rivian Automotive, Lowers Price Target to $19

Scotiabank analyst Tanya Jakusconek maintains Barrick Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>) with a Sector Outperform and lowers the price target from $25 to $24.

GOLD

Scotiabank Maintains Sector Outperform on Barrick Gold, Lowers Price Target to $24

Piper Sandler analyst Thomas Champion maintains Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) with a Neutral and raises the price target from $125 to $145.

ABNB

Piper Sandler Maintains Neutral on Airbnb, Raises Price Target to $145

Scotiabank analyst Maher Yaghi maintains BCE (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BCE#TSX">BCE</a>) with a Sector Perform and lowers the price target from C$47.5 to C$45.

TSX:BCE

Scotiabank Maintains Sector Perform on BCE, Lowers Price Target to C$45

The Fed's widely anticipated 25 basis point rate cut on Thursday left investors with a sense of relief – but not certainty. According to JPMorgan analyst Maia G Crook. <a href="https://www.benzinga.com/federal-reserve">While Federal Reserve</a> Chair Jerome Powell acknowledged the U.S. economy's resilience, inflation remains a nagging issue.
In the post-meeting press conference, Powell highlighted key growth drivers, including robust consumer spending and a solid labor market.
However, he attributed persistent inflation, or the &#8220;elephant in the conference room,&#8221; largely to lagging pressures, such as shelter and insurance costs, underscoring that the fight against rising prices is far from over.
She notes that while Powell signaled some progress, he avoided providing a clear path forward, emphasizing the Fed's "data-dependent" approach.
Read Also: <a href="https://www.benzinga.com/news/large-cap/24/11/41826586/wall-street-closes-at-record-highs-after-reassurance-from-powell-magnificent-7-hit-17-trillion-tre">Wall Street Hits Record Highs After Powell&#8217;s Speech, Lifts Magnificent 7 Stocks To $17 Trillion In Historic Trading</a>
<h2 class="wp-block-heading">What's Next For December?</h2>
Crook expects another 25 basis point cut in December, followed by quarterly cuts in 2025, but warns the Fed might hold off if the inflation rate doesn't continue to ease. With Powell leaving options open, she suggests the Fed's caution reflects a genuine concern over stubborn inflation that could delay the easing path investors hope for.
ETFs such as the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), the iShares Core S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVV#NYSE">IVV</a>) and the Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) provide exposure to broad market U.S. equities.
<h2 class="wp-block-heading">Politics In The Background</h2>
When asked about the impact of the recent election, Powell stressed that policy decisions will remain apolitical, emphasizing that he would not step down if asked and can't legally be removed from his position. Crook notes that Powell's clarification here reaffirms the Fed's independence, reassuring markets wary of potential political pressures.
She sees the Fed as ready for a December cut, but with inflation still looming large, investors should remain cautious. As Powell sidesteps firm guidance, the Fed's data-driven approach means a slower path is on the table if inflation remains stubborn.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41823887/powell-dismisses-talk-of-resignation-after-trump-victory-says-policy-is-still-res">Powell Dismisses Talk Of Resignation After Trump Victory, Says &#8216;Policy Is Still Restrictive&#8217;</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Macro Economic Events

Economics

Federal Reserve

Fed Cuts Interest Rates, But Inflation Remains Elephant In The Room

Offerings

NMHI

Nature's Miracle Holding Prices Public Offering For Aggregate Gross Proceeds Of $3M

Piper Sandler analyst Clarke Jeffries maintains Amplitude (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPL#NASDAQ">AMPL</a>) with a Neutral and raises the price target from $9 to $11.

AMPL

Piper Sandler Maintains Neutral on Amplitude, Raises Price Target to $11

EHang Holdings' EH216-S Pilotless eVTOL Completes Debut Passenger Flights In Thailand

GCM Grosvenor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCMG#NASDAQ">GCMG</a>) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.15 by 6.67 percent. This is a 6.67 percent increase over earnings of $0.15 per share from the same period last year. The company reported quarterly sales of $122.93 million which missed the analyst consensus estimate of $123.80 million by 0.70 percent. This is a 1.00 percent increase over sales of $121.71 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

GCMG

GCM Grosvenor Q3 Adj $0.16 Beats $0.15 Estimate, Sales $122.93M Miss $123.80M Estimate

Potbelly Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBPB#NASDAQ">PBPB</a>), the iconic neighborhood sandwich shop, today announced plans to open its first shops in Georgia after finalizing a multi-unit development agreement with franchise partner Royal Restaurant Group. Through the agreement, Royal Restaurant Group, a national franchise group that successfully operates restaurant locations for global brands, will bring 15 Potbelly shops to Georgia, all in the greater Atlanta region. This is Potbelly's first development agreement in Georgia and its second with Royal Restaurant Group.&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;

PBPB

Potbelly Announced Plans To Open Its First Shops In Georgia After Finalizing A Multi-Unit Development Agreement With Franchise Partner Royal Restaurant Group

Guidance

BLMN

Bloomin' Brands Sees Q4 Adjusted EPS Of $0.32-$0.42 Vs. $0.67 Estimate, Projects U.S. Comparable Restaurant Sales To Fall In The Range Of (2)%-(1)%

SPPL

SIMPPLE Ltd. Forms Distribution Partnership With Mode Technology In New Zealand; Wins CleanNZ Expo 2024 Award For SIMPPLE Robotics; Partnership Anticipated To Generate $1.1M Revenue By Year-End

Piper Sandler analyst Brent Bracelin maintains BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) with a Neutral and raises the price target from $51 to $60.

Piper Sandler Maintains Neutral on BlackLine, Raises Price Target to $60

Ginkgo Bioworks Holdings (DNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mark Mas...

Ginkgo Bioworks Holdings: Sell Rating Affirmed with Revised Valuation and Price Target

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ginkgo Bioworks Holdings (DNA – Research Report), BioMarin Pharma...

Analysts Offer Insights on Healthcare Companies: Ginkgo Bioworks Holdings (DNA), BioMarin Pharmaceutical (BMRN) and Tactile Systems Technology (TCMD)

Stocks hitting all-time highs: JPM, KO, LMT, UNH, and more

Ginkgo Bioworks regains compliance with NYSE minimum bid price requirement

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2024 Update

Brendan Smith, an analyst from TD Cowen, maintained the Buy rating on Ginkgo Bioworks Holdings (DNA – Research Report). The associated price target...

Ginkgo Bioworks Holdings: A Buy Rating on Strategic AI Advancements and Market Expansion

The Top Five short crowded stocks in each U.S. sector

Guggenheim SMid Cap Value Fund Q2 2024 Commentary

Interest Rate Regimes And ARKG: Underperformance Explained

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bausch + Lomb Corporation (BLCO – Research Report)...

Analysts Offer Insights on Healthcare Companies: Bausch + Lomb Corporation (BLCO), Ginkgo Bioworks Holdings (DNA) and Eli Lilly & Co (LLY)

AAPL

ACHC

ADBE

ADPT

AMKR

AMZN

APLE

ARKG

ASIX

AVGO

AVNW

BBIO

BEPC

BIRD

BLCO

BMBL

BMRN

CABO

CBRL

CDNA

CERT

CMTL

COHR

CRSP

DASH

DDOG

DLTR

ECVT

ENOV

EVRG

EVTC

EWTX

EXAS

FANG

FDMT

FERG

IART

INBX

INST

IONS

LBPH

LDOS

MGPI

MNTK

MSFT

NAMS

NAPA

NEWT

NFLX

NTLA

NTST

NXDT

ORIC

PACB

PDCO

PEPG

PHVS

REXR

ROIV

RPRX

RXRX

SDGR

SIRI

TCMD

TMUS

TROW

TRVI

TTWO

TWST

ULCC

VKTX

VTLE

WDAY

Press Releases

Ginkgo Bioworks Reports Second Quarter 2024 Financial Results

Ginkgo Bioworks Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Ginkgo Bioworks Holdings, Inc. Common Stock - DNA

Ginkgo Regains Compliance with NYSE Minimum Bid Price Requirement

Ginkgo Bioworks Launches New Protein LLM and Model API Built on Google Cloud Technology

Ginkgo Bioworks Launches Ginkgo Datapoints to Transform AI Model Training in Biology

Pomerantz LLP Announces that this is a Reminder of a Proposed Class Action Settlement on Behalf of Purchasers of Ginkgo Bioworks Holdings, Inc. Common Stock - DNA

NOVUS Leverages Ginkgo Bioworks to Develop Innovative Feed Additives for Animal Agriculture

Comments

Ginkgo Bioworks Holdings

Vendite allo scoperto

Ginkgo Bioworks Holdings (NYSE:DNA) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO